Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Stock Information for Cue Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cue Biopharma Inc.

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
Cue Biopharma Announces Proposed Public Offering
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Cue Biopharma to Host Business Update Call and Webcast
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.